Anti ganglioside GD3 antibodies and uses thereof
US9205157B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2012 |
| Grant date | Dec 8, 2015 |
| Priority date | — |
| Expiry date | Oct 15, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to complementarity determining region (CDR)-grafted humanized R24 antibodies that bind to the GD3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine R24 antibody, and the humanized antibodies are useful in treating cancer (e.g. Melanoma).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.